BioArctic AB (publ) (STO:BIOA.B)
318.40
+7.40 (2.38%)
Mar 25, 2026, 4:29 PM CET
BioArctic AB Revenue
In the year 2025, BioArctic AB had annual revenue of 2.00B SEK with 676.80% growth. BioArctic AB had revenue of 184.04M in the quarter ending December 31, 2025, with 81.79% growth.
Revenue
2.00B
Revenue Growth
+676.80%
P/S Ratio
13.80
Revenue / Employee
15.26M
Employees
131
Market Cap
27.59B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.00B | 1.74B | 676.80% |
| Dec 31, 2024 | 257.35M | -358.64M | -58.22% |
| Dec 31, 2023 | 616.00M | 386.56M | 168.49% |
| Dec 31, 2022 | 229.43M | 203.77M | 794.02% |
| Dec 31, 2021 | 25.66M | -39.54M | -60.64% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Camurus AB | 2.27B |
| Saniona AB | 434.40M |
| BioInvent International AB | 226.50M |
| Hansa Biopharma AB | 222.27M |
| Genovis AB (publ.) | 129.65M |
| Egetis Therapeutics AB | 62.40M |
| Medivir AB | 8.50M |
| Xspray Pharma AB | 6.43M |
BioArctic AB News
- 2 days ago - New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress - PRNewsWire
- 25 days ago - Number of shares and votes in BioArctic AB (publ) as of February 27, 2026 - PRNewsWire
- 5 weeks ago - BioArctic AB (publ) (BRCTF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - BioArctic Interim Report for the period October - December 2025 - PRNewsWire
- 6 weeks ago - Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET - PRNewsWire
- 6 weeks ago - BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China - PRNewsWire
- 6 weeks ago - Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025 - PRNewsWire
- 3 months ago - Leqembi included in China's commercial insurance innovative drug list - PRNewsWire